{"id":"NCT00196326","sponsor":"Duramed Research","briefTitle":"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive","officialTitle":"A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose, Combination Oral Contraceptive, Which Utilizes Ethinyl Estradiol During the Seven Day Interval Between Each 84-day Cycle","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2007-06","completion":"2007-06","firstPosted":"2005-09-20","resultsPosted":"2009-04-15","lastUpdate":"2016-11-16"},"enrollment":2235,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"DR-1011","otherNames":["levonorgestrel/ethinyl estradiol"]}],"arms":[{"label":"DR-1011","type":"EXPERIMENTAL"}],"summary":"This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.","primaryOutcome":{"measure":"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining \"On Drug\" Pregnancy","timeFrame":"up to one year","effectByArm":[{"arm":"DR-1011","deltaMin":2.44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":55,"countries":["United States"]},"refs":{"pmids":["20004272"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":2185},"commonTop":["HEADACHE","NASOPHARYNGITIS","DYSMENORRHOEA","NAUSEA","METRORRHAGIA"]}}